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Abstract
Type 2 diabetes contributes to significant risk of cardiovascular and micro-vascular complications. The family practitioner 
plays a significant role in the management of glycaemic control and thereby reducing the related morbidity and mortality. 
Monitoring of blood glucose control has become an integral part of disease management that can empower patients and 
physicians to optimal blood glucose management. 
Numerous drugs are currently available to treat type 2 diabetic patients. The role of the currently available drugs is discussed 
as well as the use of insulin. A suggested protocol for the initiation and adjustment of treatment is provided.
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INTRODUCTION
The family practitioner plays a crucial 
role in the management of type 2 dia-
betes patients, not only in the preven-
tion and early diagnosis of diabetes 
but also in the long-term follow-up and 
repeated adjustments necessary.  The 
family practitioner is in the ideal posi-
tion to maintain close patient contact, 
since he/she is the entry point for most 
patients into the health system, and 
have the most frequent patient contact. 
This also makes the family physician the 
ideal person to do patient education 
and monitoring of progress of glycae-
mic control as well as management of 
other cardiovascular risk factors which 
contribute to a significantly higher risk in 
diabetic patients.
All patients with type 2 diabetes 
should understand that the disease is 
progressive and that blood glucose 
treatment should frequently be reas-
sessed and adjusted. A clear under-
standing of this fact is also important for 
the caring physician who might become 
disheartened if treatment seems only 
temporarily effective and glycaemic 
control frequently elusive. Both the 
patient and the physician should know 
and understand that all type 2 diabetic 
patients might deteriorate to a stage 
where insulin therapy is essential to con-
trol blood glucose. This fact also makes 
it essential that insulin injections should 
never, at any stage of diabetes man-
agement, be used to threaten patients 
to improve compliance.1
This article will focus on the following 
challenges/dilemmas of glucose control 
in family practice: 
•  The progressive nature of type 2 dia-
betes leading to deteriorating blood 
glucose control  
•  The value and limitations of glucose 
monitoring, and how to interpret mea-
surements
• How to initiate/adjust therapy
GLYCAEMIC TARGETS FOR TYPE 2 
DIABETES MELLITUS (DM)
Glucose control is essential in type 2 
DM, as was clearly demonstrated in the 
United Kingdom Prospective Diabetes 
study (UKPDS), where improved glu-
cose control decreased the frequency of 
microvascular complications (nephrop-
athy and neuropathy).2,3 The UKPDS 
showed  that glucose control improved 
macrovascular outcomes although not 
statistically significant,  but a recent 
meta-analysis of 10 prospective cohort 
studies showed that the relative risk is 
1.18 for each 1 percent increase in the 
HbA1c.4 In other words, for every 1 % 
increase in HbA1c the risk of cardiovas-
cular disease increases by 18%). The 
American Diabetes Association (ADA) 
recommends the lowering of HbA1c to 
less than 7% in general and less than 
6% (normal) in individual patients, pro-
vided that significant hypoglycaemic 
episodes can be avoided.5 It makes 
sense that both the pre- and post-pran-
dial blood glucose should be optimally 
controlled (< 8 mmol/L fasting, and < 10 
post-prandial), since both fasting and 
prandial blood glucose contribute to the 
HbA1c. There is insufficient proof that 
optimal control of prandial blood glu-
cose is associated with less micro- and 
macro-vascular complications.6
The South African national guidelines 
set optimal glycaemic control targets 
at 4 to 6 mmol/L fasting, and 5 to 8 
mmol/L 2 hours post-prandial, as well 
as an HbA1c of less than 7%.7 These 
targets are essentially the same as 
those of the Society for Endocrinology 
Metabolism and Diabetes of South Af-
rica (SEMDSA).8
GLUCOSE HOME MONITORING IN 
PATIENTS WITH TYPE 2 DIABETES
Self-monitoring of blood glucose 
(SMBG) is an essential component of 
diabetes care. There are a variety of 
options regarding the optimal testing 
schedule for patients.
In a large US-based cohort study (24 
312 patients with type 1 and type 2 
diabetes), HbA1c was lower in patients 
who regularly did SMBG. For type 2 
patients on oral treatment alone and 
on diet alone, the difference was 0.6 
and 0.4% respectively.9 The most re-
cent systematic review concluded that 
SMBG was associated with an improve-
ment of HbA1c of 0.39%. Some of the tri-
als on which this conclusion was based 
seem to be of poor quality, which makes 
interpretation difficult.10
The American Diabetes Association 
(ADA) states that the optimal timing and 
frequency of SMBG in patients on oral 
agents or diet only is not known, but that 
it should be individualised for each pa-
tient in order to achieve blood glucose 
goals.5 Patients with type 2 diabetes on 
insulin need to perform SMBG more of-
ten. Patients should also do SMBG more 
often after their treatment has been 
adjusted.
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The ROSSO study investigated the out-
come of type 2 diabetic patients who do 
SMBG.11 It demonstrated that morbidity 
and mortality were significantly lower in 
patients doing SMBG (adjusted hazard 
ratios 0.68 and 0.49 respectively). In 
other words morbidity and mortality was 
respectively 32% and 51% lower in pa-
tients who do SMBG. This improvement 
was independent of whether the patients 
were on oral, insulin or a combination of 
oral and insulin therapy. 
The national guidelines of the South 
African Department of Health suggest 
that patients with type 2 diabetes should 
test blood glucose fasting and two 
hours post-prandially once or twice a 
week until glucose levels are normal.7 
Once blood glucose is normal, fasting 
blood glucose should be checked once 
a month if the patient is on diet and oral 
agents.  This is in general not achievable 
in the South African public health system 
since most patients do not have access 
to home monitoring due to the inability of 
public health care facilities to supply the 
necessary glucometers and strips. 
Patients on insulin should do SMBG 
as in type 1 diabetes patients: four 
times daily during an intensive effort to 
improve glycaemic control (before each 
meal and at bedtime). This can be re-
duced to twice daily before meals and at 
bedtime, choosing a different meal each 
day once control is achieved. The alter-
native is a four times a day profile done 
twice weekly, once on a working day 
and once during the weekend. Blood 
glucose should also be tested between 
3 am and 4 am once or twice a month.12 
Blood glucose monitoring is a useful 
tool to motivate patients to change their 
behaviour and to comply with treatment 
schedules. The author is also of the 
opinion that keeping record of blood 
glucose measurements is important to 
detect patterns of poor glucose control 
and to implement appropriate interven-
tions.
Day profiles (the measurement of 
blood glucose seven to eight times 
a day, before meals, two hours after 
meals, at bedtime and, if necessary, be-
tween 2 am and 4 am) can be extremely 
useful in identifying hyperglycaemic 
episodes in patients in whom there are 
discrepancies between capillary blood 
glucose recorded and HbA1c levels. 
This can be done if poor control is pres-
ent, as indicated by the HbA1c, and 
should be done for two to three days, 
usually including a weekend day.
HbA1c
HbA1c is a reflection of blood glucose 
control during the preceding two to 
three months. This test should be done 
two to four times a year and, if possible, 
at the time of patient contact. This opens 
an opportunity for patient education and 
motivation, as well as an opportunity to 
change therapy if needed. The patient 
cannot manipulate the result, as may 
happen with a random glucose mea-
surement.5,13
The HbA1c should always be cor-
related with the patient’s SMBG and the 
results must be discussed with the pa-
tient in order to make well-informed de-
cisions. Be aware that even frequently 
done SMBG can miss significant hyper-
glycaemic episodes, which can have 
an influence on the HbA1c. If such a 
discrepancy occurs, the patient should 
be requested to test more regularly or to 
do a glucose day profile. These discrep-
ancies frequently occur in patients who 
are measuring capillary blood glucose 
fewer than two times a day, especially if 
it is only done pre-prandially.14,15
Take note that inaccurate HbA1c 
values occur in conditions with rapid red 
blood cell turnover, in patients with HIV 
and in renal failure.16,17,18
OFFICE AND FASTING PLASMA 
GLUCOSE MEASUREMENTS
Fasting plasma glucose correlates with 
HbA1c in type 2 diabetic patients, since 
the fluctuations in blood glucose are not 
as severe as in type 1 diabetic patients. 
It thus can give an indication of glycae-
mic control, but does not replace the 
HbA1c as a measure of blood glucose 
control.19
Non-fasting blood glucose monitor-
ing can be a good indicator of blood 
glucose control, but caregivers should 
be cautious to use a single office blood 
glucose measurement to adjust treat-
ment.20
The author is of the opinion that pa-
tients frequently behave differently on 
days that they visit the diabetic clinic. 
They tend to skip meals or inject more 
insulin a few days before they visit 
clinics. It is for this reason that office 
capillary blood glucose measurements 
should not be used as the only mea-
sure to assess blood glucose control 
to adjust treatment. Home monitoring or 
HbA1c should rather be used to adjust 
therapy instead of a single office blood 
glucose value to adjust therapy.
THE EFFECT OF NON-PHARMACO-
LOGICAL AND PHARMACOLOGICAL 
INTERVENTIONS ON GLUCOSE LEV-
ELS
Diet, weight reduction and exercise
All patients should receive individu-
alised nutritional advice by a registered 
dietician or a family physician who is 
knowledgeable in diabetes nutritional 
care.5 Carbohydrate counting, carbohy-
drate exchanging, glycaemic index and 
glycaemia load are all important con-
cepts and, when implemented, could 
improve glycaemia control.21 
Dietary intervention can improve 
various aspects of type 2 diabetes, 
including improvement of insulin sensi-
tivity and secretion. For overweight and 
obese patients, significant benefit can 
be gained with regard to lowering the 
blood glucose if body mass is reduced. 
In the UKPDS study a patient with mildly 
elevated fasting blood glucose of 6 to 8 
mmol/L a 10 kg weight loss (16% of ini-
tial body weight) was needed to achieve 
a persistent fasting blood glucose below 
6 mmol/L. If fasting blood glucose was 
above 14 mmol/L patients needed to 
lose on average 26 kg of body weight 
(41% of initial weight) in order to achieve 
the same effect. 22,23 A slow but progres-
sive weight loss strategy with a moder-
ately reduced caloric diet in conjunction 
with lifestyle changes, including an 
increase in physical activity, should 
be advised.24 The majority of diabetic 
patients are unable to maintain weight 
loss. This is most likely due to a lower-




Principles of pharmacological treat-
ment of type 2 diabetes
•  Insulin should be started whenever 
the fasting blood glucose exceeds 15 
mmol/l, or if significant unexplained 
weight loss has occurred, or if the 
patient is ketotic.26
•  Combining drugs is usually more ef-
fective than stopping one agent and 
introducing another.
•  Adding a second agent is usually 
better than increasing the dose of 
one that is already near maximum 
dosage.
•  Secondary failure of two drug combi-
nations can eventually be expected.
•  Three drug combinations may be 
useful, but evidence of added ef-
ficacy is lacking.
•  Failure of two oral drug combinations 
usually calls for the use of insulin, 
alone or in combination with oral 
agents.
Oral agents
Currently, five classes of oral hypogly-
caemic agents are available in South 
Africa, of which only the biguanides and 
sulphonylureas are listed in the essen-
SA Fam Pract 2006:48(10)26
CPD Article
tial drug list (EDL).27 All the oral agents 
used as single therapy can be expected 
to lower the HbA1c by between 0.5 and 
2% (absolute). Combination therapy 
will achieve additive reductions in the 
HbA1c (see Table I).
There are three basic mechanisms 
of action of oral hypoglycaemic agents 
for reducing blood glucose.
The first mechanism is augmentation 
of the release of insulin from pancreatic 
β-cells (potentiate glucose-mediated 
insulin secretion). This is achieved via 
the binding of sulphonylureas to the sul-
phonylurea receptor (SUR) unit, which, 
with a second subunit (Kir), triggers 
closure of the ATP-sensitive potassium 
channels, opening voltage sensitive 
calcium channels, with an influx of 
calcium that stimulates translocation 
of insulin-containing granules to the 
plasma membrane and the release of 
insulin. The meglitinides have a similar, 
but not exactly the same, mechanism of 
action: they bind to a different site on 
the SUR subunit of the ATP-dependent 
potassium channel. This explains why 
suphonylurias and meglitinides should 
not be used in combination.28
The second mechanism is the increase 
in insulin sensitivity. Metformin achieves 
this by the suppression of hepatic 
glucose production, increased insu-
lin-mediated muscle glucose uptake, 
decreased  fatty acid oxidation and 
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Abbreviations: HbA1c: glycosylated haemoglobin A1c; TG: triglycerides; LDL: low density lipoprotein cholesterol; HDL: high-density lipo-
protein cholesterol
increased  intestinal glucose utilisation. 
The exact molecular mechanisms for 
Metformin action is not yet clearly under-
stood, but activation of the AMP-activat-
ed protein kinase seems to play a major 
role.29 The thiazolidinediones exert their 
effects by activation of the peroxisome 
proliferator-activated nuclear receptor 
(PPAR). When this receptor is activated, 
glucose transporter gene transcription 
is mediated, with increased glucose 
transport across cell membranes. Since 
thiazolidinediones (TZD) action is medi-
ated via gene transcription, its maximal 
effect is only achieved after three to six 
weeks.30
The third mechanism whereby oral 
anti-diabetic agents exert their effect 
is delaying the absorption of carbohy-
drates from the intestines. The α-glu-
cosidase inhibitors are competitive sup-
pressants of the small intestine’s brush 
border enzymes, which are needed to 
hydrolyse oligosaccharides and poly-
saccharides to monosaccharides.31
WHEN TO USE WHICH DRUG
In most patients the first line of treatment 
is either sulphonylurea (SU) or Metfor-
min. Metformin has the advantage of 
moderate weight loss or stabilisation 
of body weight. This makes it the ideal 
choice for overweight and obese pa-
tients with diabetes.32
SU and meglitinides are more or 
less equally effective in blood glucose 
lowering; the meglitinides have the 
advantage of increasing early prandial 
insulin secretion, which makes it ideal 
for patients with high prandial blood 
glucose peaks. In contrast to sulphonyl-
ureas, the meglitinides have little effect 
on insulin secretion between meals and 
during the night. The major advantage 
of sulphonylureas is their ability to lower 
blood glucose on a once daily dosing 
schedule with the newer drugs, and 
their reasonable price.33
The thiazolinediones (TZD) are useful 
in patients with significant insulin resis-
tance. Although they can be used as 
monotherapy, they are more frequently 
used as second line therapy in combi-
nation with other agents or insulin. TZDs 
are more expensive than Metformin, and 
cause more weight gain.28
The α-glucosidase inhibitor (Acar-
bose) is effective for a reduction in 
post-prandial glucose peaks, and is 
mostly used in combination with other 
oral antidiabetic drugs or insulin. Due 
to its mechanism of action, Acarbose 
tends to cause abdominal distension, 
flatulence and diarrhoea.31Due to the 
progression of β-cell depletion in type 2 
diabetic patients, a significant propor-
tion of patients will develop insufficient 
glycaemic control on oral agents alone 
or will need insulin after initial control on 
diet and oral treatment.35
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Insulin started immediately*
Consider changing to oral agents when
glucose is well controlled for a few
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NPH / Glargine / Detemir insulin at
at night & Metformin / Glitazone
Mixed insulin twice daily ±
Metformin / Glitazone
Uncontrolled
Basal + Prandial insulin ± Metformin /
Glitazone
Continue
When initiating insulin in
combination with oral treatment,
start with 0.2 U/kg
When insulin is used alone,
start with 0.4 - 0.5 u/kg
Fig 1: Insulin in type 2 diabetic patients
Adapted from 7,8,32
Beta-cell exposure to prolonged hy-
perglycaemia leads to a loss of respon-
siveness to glucose. This reversible 
β-cell exhaustion is also called glucose 
toxicity and is characterised by a fasting 
plasma glucose level higher than 13.9 
mmol/L. The β-cell function may recover 
after a few weeks of intensive glycaemic 
control, which is attained by temporary 
insulin therapy.36,37
If diabetic patients are started on 
insulin treatment, it is preferable to con-
tinue with oral therapy, especially Met-
formin, since this has a limiting effect on 
weight gain due to insulin.38,39
Traditionally, insulin was used in type 
2 diabetic patients when hyperglycae-
mia persisted despite diet and maxi-
mum oral therapy.40 Currently, there is 
more and more evidence to suggest 
earlier exogenous insulin administra-
tion.26,41 Due to the decline of beta cell 
function (loss of first phase and delayed 
and inadequate second phase insulin 
secretion) mealtime insulin administra-
tion may be needed earlier than what 
was traditionally given in an attempt 
to delay β-cell depletion and allow for 
β-cell recovery.42 The threshold fasting 
blood glucose level where the initiation 
of insulin therapy should be considered 
as the initial treatment of type 2 diabetes 
varies from 13.9 mmol/L to 16.7 mmol/
L.12,33,36,37 
Insulin therapy should also be initi-
ated if unintended, unexplained weight 
loss or ketonuria is present. Temporary 
insulin therapy may also be needed 
during episodes of acute illness.43 With 
insulin, glycaemic control can always be 
achieved and it can be initiated at any 
stage in type 2 diabetic patients.
Insulin therapy can be implemented in 
numerous ways and a wide variety of 
insulins are available. Healthcare pro-
viders need to consider each patient’s 
ability and individual circumstances to 
select the optimal way to control blood 
glucose.44
Three aspects of insulin therapy need 
to be considered in patients receiv-
ing insulin: basal insulin requirements, 
prandial (bolus) insulin requirements 
and, lastly, adjustments of insulin. In 
type 2 diabetic patients, not all three 
aspects should initially be replaced, 
since residual β-cell function may still be 
present. As the disease progresses to 
total depletion of β-cell function, all three 
aspects should be addressed.
The traditional way to start insulin in type 
2 diabetic patients is to initiate basal in-
sulin with NPH or isophane insulin once 
daily, usually at bedtime, when oral 
agents alone are insufficient to control 
blood glucose.45 Newer, peak-less ana-
logue insulin glargine or detemir seem 
to be very effective for this purpose, and 
also pose a smaller risk of hypoglycae-
mia.46,47 Basal insulin should be adjusted 
according to fasting morning blood 
glucose levels. The usual starting dose 
is 0.1 to 0.2 U/kg per day. This strategy 
should be seen as an augmentation of 
β-cell function and should be used in 
conjunction with oral agents, especially 
sulphonylureas or meglitinides. 
Beta-cell function can also be aug-
mented by the addition of meal-related 
regular or short-acting analogue insulin 
(Aspart/Lispro/Glulisine).48,49,50 Post-
prandial glucose should be monitored 
and the insulin dose adjusted to these 
measurements, with the aim of keeping 
it below 10 mmol/L. This strategy makes 
good sense because insulin deficiency 
is usually most pronounced during 
meals and shortly afterwards in diabetic 
patients. This strategy is not frequently 
followed, because numerous injections 
are required unless total replacement of 
insulin is indicated, in which case basal 
insulin and an adjustment plan accord-
ing to pre-meal glucose are added.
Both basal and prandial insulin re-
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quirements can be satisfied by giving 
combination insulin (premixed Regular 
and NPH / Isophane insulin or newer bi-
phasic insulin Aspart and Lispro) twice 
daily.51,52,53 The disadvantage of this 
strategy is that a fixed meal schedule 
needs to be followed. The two advan-
tages of the newer analogue insulin 
mixtures is that a much less pronounced 
insulin peak is present in the basal com-
ponent of the dosage54 and the second 
is that only two injections need to be 
given daily. The newer insulin analogue 
mixed insulins  seem, however, to give 
even better results if given three times 
per day immediately before meals.55
Glycaemic control can also be 
achieved by the administration of basal 
insulin (NPH / Isophane / Glargine / De-
temir56) with mealtime boluses (Aspart/
Glulisine), which allows the greatest 
flexibility with regard to eating habits. 
This is also known as the basal bolus 
regimen.57 This strategy, especially if ap-
plied with new analogue insulins, allows 
for insulin administration immediately 
before meals (Aspart/Lispro/Glulisine) 
and provides a constant supply of basal 
requirements (Glargine / Detemir) with-
out the need to take snacks between 
meals.58 This strategy is usually applied 
in patients with very little remaining β-
cell function.
It is important that initiating insulin 
should never be seen as failure on the 
part of the patient to comply with oral 
therapy; it should rather be seen and 
explained as the normal progression of 
disease. Secondly, patients should be 
prepared for the possibility that insulin 
might be needed at some stage in the 
future as part of disease management. 
However the patient should never see 
insulin treatment as a punishment for 
poor diet and oral treatment compli-
ance.59 
In community health centres in Cape 
Town, unsatisfactory glycaemic control 
in type 2 diabetic patients was found to 
be due to barriers against the initiation 
of insulin. The reasons  related to the 
doctors were: a lack of knowledge, lack 
of experience with and the use of guide-
lines related to insulin therapy, language 
barriers between doctors and patients, 
and the fear of hypoglycaemia. Patient 
barriers included: wrong beliefs about 
insulin, non-compliance, lack of under-
standing of diabetes, use of traditional 
herbs, fear of injections and poor socio-
economic conditions. System barriers 
included inadequate time, lack of conti-
nuity of care and financial constraints.60 
The author believes that these barriers 
are not only present in Cape Town, but 
are prevalent in the whole country. It 
therefore is every healthcare provider’s 
responsibility to gain sufficient knowl-
edge and to educate patients regard-
ing the progressive nature of type 2 
diabetes and not to delay the initiation of 
insulin when needed.
CONCLUSION
The management of type 2 diabetes is 
complex, with numerous options. The 
appropriate option for each patient will 
be determined by the patient’s ability to 
cope with a regimen, patient preferences 
and, frequently, by the patient’s ability to 
afford the medication. Independent of 
what treatment regimen is prescribed, all 
patients should be educated on the im-
portance of glycaemic control and how 
to use treatment optimally. Due to the 
chronic nature of diabetes it is essential 
that all patients should be kept motivated, 
which calls for a motivated, tenacious, 
supportive health caregiver. 
See CPD Questionnaire, page 48
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